EU to negotiate major vaccine contract extension with Pfizer
The head of the European Union's executive arm has announced plans for a major contract extension for COVID-19 vaccines with Pfizer stretching to 2023
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.EU Commission chief Ursula von der Leyen announced plans Wednesday for a major contract extension for COVID-19 vaccines with Pfizer stretching to 2023.
In a sign of confidence in a company that has been a mainstay of Europe's vaccination drive so far, von der Leyen said the EU will start negotiating to buy 1.8 billion doses of the Pfizer-BioNTech vaccine through 2023.
Von der Leyen expressed full confidence in the technology used for the Pfizer-BioNTech vaccine, which is different from the technology behind the Oxford-AstraZeneca vaccine.
“We need to focus on the technologies that have proven their worth,” von der Leyen said.
Pfizer-BioNTech plans to provide the EU with an extra 50 million dozes in the 2nd quarter of this year, on top of 200 million doses already earmarked for the bloc. The deliveries will be especially welcomed by the EU's 27 member nations considering supply delays and concerns over rare blood clots potentially linked to the Oxford-AstraZeneca vaccine.
Denmark decided Wednesday not to resume use of AstraZeneca COVID-19 vaccine after putting it on hold last month following reports of rare blood clots in some recipients. The bulk of the shots given in the Scandinavian country so far have been the Pfizer-BioNTech vaccine.
The European Commission currently has a portfolio of 2.3 billion doses from a half dozen companies and is negotiating more contracts.
The planned negotiations with Pfizer left in the middle what the EU would do about any new contracts with AstraZeneca, which has had massive delivery problems during the first quarter and expects to send far fewer vaccines than its contract with the EU called for during the second quarter.
The European Commission said in a statement, “We keep all options open to be prepared for the next stages of the pandemic, for 2022 and beyond. We can, however, not comment on contractual issues.”
Von der Leyen, however, showed her full support for Pfizer-BioNTech, with the announcement for the massive order.
___
Jan Olsen contributed from Copenhagen.